MTOR and COVID-19: In a retrospective cohort study by Peron et al. [9], they evaluated 102 Italian individuals with TSC and/or LAM to evaluate the possible effects of mTOR inhibitors on COVID-19 with results suggesting no increased risk of developing COVID-19 as none of the patients on mTOR inhibitors developed confirmed COVID-19 infection [9]. Following the Peron et al. study, Baldi et al. [10], conducted a retrospective study to assess LAM, COVID-19, and the role of mTOR inhibitors in patients from Brazil.